Aurora A Kinase Inhibitor Shows Promise in Phase I for NHL and CLL

A new chemotherapy drug (alisertib or MLN8237) being investigated for its potency against two types of cancer was found by scientists to be effective in about one-third of the 58 patients who participated in a phase I study.

ew chemotherapy drug being investigated for its potency against two types of cancer was found by scientists at Houston Methodist and seven other institutions to be effective in about one-third of the 58 patients who participated in a phase I study.

A n

The drug, alisertib or MLN8237, inhibits the enzyme aurora A kinase, which is known to be very active during cell division. The present study, published in the journal Investigational New Drugs, looks at the safety, tolerability, and preliminary success of alisertib in treating non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

"An advantage with this drug is it is oral and very effective in a significant number of patients with aggressive lymphoma when used at that dose for 7 days out a 21 day cycle," said hematologist Swaminathan Iyer, M.D., who led the multi-site study.

Read the complete report here: http://bit.ly/1oEG2GO

Source: ScienceDaily